DOCSLIB.ORG

Overal Suvival

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overal Suvival US 20190025310A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0025310 A1 DUVAL et al. (43 ) Pub . Date : Jan . 24 , 2019 (54 ) METHODS FOR PREDICTING THE Publication Classification SURVIVAL TIME OF PATIENTS SUFFERING (51 ) Int. CI. FROM A MICROSATELLITE UNSTABLE GOIN 33 /574 (2006 .01 ) CANCER (52 ) U .S . CI. ( 71 ) Applicant: INSERM ( INSTITUT NATIONAL CPC . .. GOIN 33 /57419 ( 2013 .01 ) ; GOIN 2800 / 56 DE LA SANTE ET DE LA (2013 . 01 ) ; GOIN 2800 /52 ( 2013 .01 ) ; GOIN RECHERCHE MEDICALE ) , Paris 2333/ 90241 (2013 .01 ) (FR ) (72 ) Inventors : Alex DUVAL , Paris ( FR ) ; Thierry ( 57) ABSTRACT ANDRE , Paris ( FR ) ; Magali SVRCEK , Paris ( FR ) ; Aurelien DE The present invention relates to methods for predicting the REYNIES , Paris (FR ) ; Laetitia survival time of patients suffering from a micro satellite MARISA , Paris (FR ) unstable cancer . In particular, the present invention relates to a method for predicting the survival time of a patient (21 ) Appl. No. : 16 / 066, 949 suffering from a micro satellite unstable cancer comprising i ) determining the expression level of at least one gene (22 ) PCT Filed : Dec . 28 , 2016 encoding for an immune checkpoint protein in a tumor tissue sample obtained from the patient, ii ) comparing the expres ( 86 ) PCT No. : PCT/ EP2016 /082745 sion level determined at step i ) with a predetermined refer ence value and iii ) concluding that the patient will have a $ 371 ( c) ( 1 ), long survival time when the level determined at step i ) is ( 2 ) Date : Jun . 28 , 2018 lower than the predetermined reference value or concluding ( 30 ) Foreign Application Priority Data that the patient will have a short survival time when the level determined at step i ) is higher than the predetermined Dec . 29, 2015 ( EP ) .. .. .. 15307157 . 6 reference value . CIT + TCGA series . - - - - - - - - : OLO : - - - - - - - . - 1 . B - - - - - - - - - . - - - - - - - - - OverallSurvival - - - - . - - cms 1 :- - - . - - - . cms2 msi cms3 p = 0 .032 1 mss p = 0 .031 7 cms4 34 4 5 Time from diagnostic (years ) Time from diagnostic (years ) Patent Application Publication Jan . 24 , 2019 Sheet 1 of 8 US 2019 / 0025310 A1 . - - - - - - - - - - - - - - - - - - - 5 cms1: cms2 cms3 cms4 4 - - - - - - - - . - - - - - - - - . - - - . 3 Timefromdiagnostic(years) 2 031.0=pp=0.051 0 CIT+TCGAseries - - - - - - - - - - - - - - - - - - - - - - - , 5 4 msi[ Imss Timefromdiagnostic(years) 3 2 032p=0.0320=p 1 0 Survival Overall Figure 1A Patent Application Publication Jan . 24 , 2019 Sheet 2 of 8 US 2019 / 0025310 A1 MSI CIT + TCGA series variable p -value HR 95 % CI. ICK 0 . 0068 3 .5 ( 1 . 4 - 8 . 5 ) TH1 0 .013 2 . 2 ( 1 . 2 - 4 . 1 ) Metagenes CTL 0 .052 1 . 7 ( 1 - 3 ) CYTOX 0 .038 1 . 6 ( 1 . 0 - 2 . 5 ) PDCD1 0 .059 2 . 8 ( 1 . 0 - 8 . 0 ) TNERSF18 0 .025 2 . 6 ( 1 . 1 - 5 . 8 ) HAVCR2 0 .016 2 . 3 ( 1 . 2 - 4 . 7 ) CD40 0 . 028 2 . 3 ( 1 . 1 - 4 . 7 ) CD274 0 .0050 2 . 2 ( 1. 3 - 3 . 9 ) LAG3 0 .017 2 . 2 ( 1. 2 - 4 . 2 ) VTCN1 0 .067 2 . 1 ( 1 . 0 - 4 . 7 ) TNFRSFS 0 . 057 2 . 0 ( 1 . 0 - 4 . 2 .) ImmuneCheckpoints+Modulator IL2RB 0 .034 1 . 8 ( 1 . 1 - 3 . 1 ) ID01 0 .0090 1 . 4 ( 1 . 1 - 1 . 8 ) TNFRSF4 0 . 1 1 . 8 ( 1 . 0 - 3 . 8 ) CTLA4 0 . 27 1 .6 ( 0 . 7 - 3 . 4 ) PDCD1LG2 0 . 16 1 . 5 ( 0 . 9 - 2 . 8 ) ICOS 0 . 16 1 . 5 ( 0 . 9 - 2 . 6 ) CD276 0 . 93 1 . 1 ( 0 . 4 - 3 . 1 ). CD3G 0 .011 2 , 7 ( 1 . 3 - 5 . 6 ) CD3E 0 .054 2 . 0 ( 1 . 0 - 3 . 9 ) CD3D 0 .099 1 . 6 (0 . 9 - 2 . 8 ) CTL PTPRC 0 .07 1 . 4 ( 1 . 0 - 1 . 9 ) CDSA 0 . 12 1 . 4 (0 . 9 - 2 . 0 ) PRF1 0 .035 1 . 9 ( 1 . 0 - 3 . 3 ) GZMH 0 .0090 1 . 7 ( 1 . 1 - 2 . 5 ) GNLY 0 .039 1 . 5 ( 1 . 0 - 2 . 3 ) GZMB 0 .033 1 . 4 ( 1 . 0 - 2 .0 ) Cytotoxicity GZMK 0 .064 1 . 4 ( 1 . 0 - 2 . 0 ) GZMA 0 . 16 1. 3 (0 . 9 - 1 , 7 ) TBX21 0 . 022 2 .6 ( 1 . 2 - 6 . 1 ) Th1 JENG 0 ,02 1. 7 . ( 1 , 1 - 2 , 8 ) . LOOD Age ( > 60 yo ) 0 . 08 2 .7 ( 0 . 9 -8 . 2 ) Sex ( M ) 0 . 12 2 .0 ( 0 . 8 -4 . 7 ) BRAF ( m ) 0 . 75 1 . 2 ( 0 . 5 - 2 . 8 ) Clinical Loc (Right ) 0 . 87 1 . 1 (0 .4 - 2 . 7 ) KRAS ( m ) 0 . 93 1 . 0 ( 0 . 4 - 2 .5 ) Lynch S 0 .68 0 . 8 ( 0 . 4 - 2 ) 0 . 25 16 . Overall Survival Hazard Ratio Figure 1B Patent Application Publication Jan . 24 , 2019 Sheet 3 of 8 US 2019 / 0025310 A1 msiICK msiICK+ Imss 12345 Timefromdiagnostic(years) p=0.024 0 mssICK mssICK+ 12345Timefromdiagnostic(years) p=0.94 msiICK ICK+msi 12345Timefromdiagnostic(years) 0490.p= 0 Survival Overall Figure 10 Patent Application Publication Jan . 24 , 2019 Sheet 4 of 8 US 2019 / 0025310 A1 value- P y ou wake LS 1 < HR 1 > HR Wit CRC(n=202) See hr=1.4 hr-1.5 31.hr= hr=1.5 hr=1, WM pv=0.33 pv=0.063 22.pv=0 hr-1.6033pv=0. pv=0.061 61.pv=0 IE S 51 46hr=0.051PV0.= WWWWW56.hr=0 ??????- py=0.021 hr=0.032.0 =pv hr=0.48 W SA CRC(n=355)100 37pv=0.024I pv=0.06611py hr-0.63=56OV=0.018Ip0181 . SHARE 92 hr=0.9 69.pv=0 br=0.86 vahr=0.9 53.pv=0 8.0=PV hr=0.73 i 1 CRC(n=29) hr=0.4 65.pv=0 hr=0.75 71.pv=0 hr=0.72 pv=0.61 hr=0.88 pv=0.91 hr=0.75 72.pv=0 46.hr=0 pv=0.32 . CIT+TCGAseries ERANT 21e-037 (n=791) hr=0.91 43.=0pv 890.hr= 19.pv=0SHONA hr=0.95 50.pv= hr=1 92.py=0 hr=0.91 33.pv=0 .82810: :6hr1 2hr-/ p=0.1 MSICRC(n=194) 0540.=py 042py0,= 015pv0.* hra17 pv=0.056 AllCRC hr=0.97 76.pv0= hr=0.94 4.pv=0 hr=0.9989 .pv=0 hr=1. pv=0.51 hr=0.95 55.pv=0 83hr0.=D=0.016 ICK CTL CYTOX IS-likev1CD3,CDBAPTPRC IS-likev2 CD8A,PTPRCGZMBMS4A1 Figure 1D Patent Application Publication Jan . 24 , 2019 Sheet 5 of 8 US 2019 / 0025310 A1 . 16 4 OSHazardRatio 0.25 Wald test 95%CIp-value (0.5-58)0.17 MSICITseries (1.5-290)0022 (0.1-5)0.17 (0.7-110)098 (0.3-19)0.53 (0.17-42)0.83 (2.-440)0.011 0.096(0.07-12) (2.-230)00082 (0.13-12)096 ICK21 CTL0.38 ICK8.7 CYTOX0.73 ICK5.3 TH10.84 ICK31 CK23 variableHR IS-Iv20.30 IS-Iv30.39 Cox 0.02 0.05 model p-value 0.042 0.012 0.010 ICK+IS-likev1 ICK+IS-likev2 Bivariate model ICK+CTL ICK+CYTOX ICK+TH1 Figure 1E Patent Application Publication Jan . 24 , 2019 Sheet 6 of 8 US 2019 / 0025310 A1 HR 95 % 0 p - value HAVORZ 3 . 3 ( 1 . 4 - 7. 9 ) 0 .007 LAG3 1 . 6 (0 . 89 - 2 . 7 ) 0 . 12 CD274 1 . 51092 5 ( 0 .92 - 2 .6A ) 0 . 1 PDCD1LG2 1. 2 ( 0 .69 - 2 .2 ) 0 . 48 PD1 0 .84 ( 0 . 47 - 1 . 5 ) 0 .56 CTLA4 0 . 79 (0 . 39 - 1. 6 ) 0 .51 ICOS 0 .68 ( 0 . 3 - 1 . 5 ) 0 .35 0 . 25 A 16 OS Hazard Ratio HR 95 % a pvalue HAVCR2 25 ( 1 . 1 -5 . 6 ) 0 . 031 CD274 18 ( 1 . 0 -0 1. 0037 LAG 15 (0 .9 - 2 .5 ) 0 . 12 PDCDUGZ 1. 5 ( 0 .74 - 32 ) 0 . 25 PDCD1 L1 ( 0 .63 - 18 ) 081 CTLA4 0 .95 ( 0 .48 - 2 } 0 . 95 ICOS 0 . 60 ( 0 . 26 - 13 ) 0 .21 0 . 25 4 16 SAR Hazad Ratio Figure 2A HR 95 % 0 p - value 23 ( 1. 10 - 4 . 90 ) 0 .023 CTL 13 ( 0 .65 - 2 .40 ) 0 . 5 CYTOX 14 (0 .78 - 2 .50 ) 0 . 27 TH1 14 ( 0 . 55 - 3 .80 ) 0 . 46 Me IS -like vl 13 (0 . 67 - 2 .6 ) 0 . 42 0 . 25 OS Hazard Ratio 16 HR 95 % a p -value ICK 2 . 2 ( 1 . 10 - 4 . 40 ) 0 . 024 CIL 1. 1 (0 .61 - 2. 20 ) 0 .67 CYTOX 1 . 4 (0 . 80 -230 ) 0 . 25 TH1 1. 7 ( 0 .68 - 4 .50 ) 0 . 25 Slike v1 1. 2 (0 .64 -23 ) 0 . 56 wowwwwwwwwww . core vwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww 0 . 25 SAR Hazard Ratio Figure 2B Patent Application Publication Jan . 24 , 2019 Sheet 7 of 8 US 2019 / 0025310 A1 p -value HR 95 % a p - value logrank ICK CTL ICK 3 . 9 (13 - 12 ) 0 .017 0 .035 CIL 0 . 55 ( 0 .21 - 1 . 4 0 .21 KCK + CYTOX ICK 5 ( 14 - 18 ) 0 .013 0 .024 CYTOX 0 .5 ( 0. 2 - 1 .3 ) 0 . 14 KCK + TH1 ICK 3 . 6 ( 12 - 11) 0 .022 0 .043 THI 0 . 49 ( 0 . 14 - 1 . 8 ) 0 .27 TI ICKHS I v1 ICK 3 . 7 ( 1- 2 - 12 ) 0 . 021 0 . 038 IS v10 . 57 ( 0 .22 - 1 . 5 ) 0 . 25 0 25 1 16 OS Hazard Ratio p - value HR 95 % CI p -value logrank ICK + CTL TCK 4 . 9 ( 1 . 6 - 15 ) 0 .0057 0 .015 CIL 0 .41 (0 . 16 - 1 ) 0 .058 ICK CYTOX ICK 3 . 8 ( 1 . 2 - 12 ) 0 .020 0 .034 CYTOX 0 .
Load more

Recommended publications
  • TNF‑Α‑Mediated Epithelial‑To‑Mesenchymal Transition Regulates Expression of Immune Checkpoint Molecules in Hepatocellular Carcinoma
    MOLECULAR MEDICINE REPORTS 21: 1849-1860, 2020 TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma RITU SHRESTHA1,2, KIM R. BRIDLE1,2, DARRELL H.G. CRAWFORD1,2 and APARNA JAYACHANDRAN1,2 1University of Queensland, Faculty of Medicine and 2Liver Cancer Unit, Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia Received June 12, 2019; Accepted January 31, 2020 DOI: 10.3892/mmr.2020.10991 Abstract. Hepatocellular carcinoma (HCC) is the ligand (PD‑L)1, PD‑L2, CD73 and B7‑H3. In contrast, reversal fastest growing cause of cancer-related deaths globally. of EMT suppressed the expression of PD‑L1, PD‑L2, CD73 Epithelial-to-mesenchymal transition (EMT) is a cellular and B7‑H3. In addition, high expression of TNF-α and PD‑L1 process that confers HCC tumor cells with the ability to evade in 422 patients with HCC was associated with poor overall the immune system. Immune escape in most tumors, including survival. The coordinate expression of TNF-α with PD‑L2 in HCC, is controlled by immune checkpoint molecules. The aim this patient cohort was associated with increased HCC recur- of the present study was to investigate the association between rence. In conclusion, the present study demonstrated a close EMT and immune checkpoint in HCC, and identify novel ther- association between immune modulator expression and EMT apeutic targets for HCC. An in vitro model of reversible EMT induction/reversal driven by TNF-α. was utilized based on cytokine tumor necrosis factor (TNF)-α treatment of HCC cell lines Hep3B and PLC/PRF/5.
    [Show full text]
  • Association of PD-1/PD-L Axis Expression with Cytolytic Activity
    Association of PD-1/PD-L axis expression with cytolytic PNAS PLUS activity, mutational load, and prognosis in melanoma and other solid tumors Ludmila Danilovaa,b,c, Hao Wanga, Joel Sunshined, Genevieve J. Kaunitzd, Tricia R. Cottrelle, Haiying Xud, Jessica Esandriod, Robert A. Andersa,c,e, Leslie Copea,c, Drew M. Pardolla,c, Charles G. Drakea,c,f, and Janis M. Taubea,c,d,e,1 aDepartment of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287; bVavilov Institute of General Genetics, Russian Academy of Science, Moscow, Russia, 119333; cThe Bloomberg-Kimmel Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; dDepartment of Dermatology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287; eDepartment of Pathology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287; and fThe Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 Edited by Antoni Ribas, Ronald Reagan University of California, Los Angeles Medical Center, Los Angeles, CA, and accepted by Editorial Board Member Tak W. Mak October 8, 2016 (received for review June 3, 2016) Programmed cell death protein-1 (PD-1)/programmed death ligand-1 infiltration and improved overall patient survival (14). Mutational (PD-L1) checkpoint blockade has led to remarkable and durable burden has also recently been demonstrated to predict response to objective responses in a number of different tumor types. A better anti–PD-1 therapy in patients with nonsmall cell lung carcinoma understanding of factors associated with the PD-1/PD-L axis expres- (NSCLC) (15).
    [Show full text]
  • Evaluating the Potential for B7-H4 As an Immunoregulatory Target
    Author Manuscript Published OnlineFirst on March 21, 2017; DOI: 10.1158/1078-0432.CCR-15-2440 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 2 Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target 3 Heather L. MacGregor1,2 and Pamela S. Ohashi1-3* 4 5 6 7 1Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, 8 Toronto, Ontario, Canada 9 2Department of Immunology, University of Toronto, Toronto, Ontario, Canada 10 3Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada 11 12 13 Running Title: Evaluating B7-H4 as a Potential Immunoregulatory Target 14 Keywords: B7-H4; immunosuppression; co-inhibitory molecule; immunotherapy; tumor 15 microenvironment 16 17 Funding sources: This work was supported by grants from the Canadian Institute for Health 18 Research awarded to P.S. Ohashi. 19 20 *Corresponding Author: Pamela S. Ohashi, Princess Margaret Cancer Centre, 610 University 21 Avenue, Suite 8-407, Toronto, Ontario M5G 2M9, Canada. Phone: 416-946-2357; Fax: 416-204- 22 2276; e-mail: [email protected] 23 Disclosures: The authors have no financial conflicts of interest. 1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 21, 2017; DOI: 10.1158/1078-0432.CCR-15-2440 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 24 (Abstract: 152 words; Body: 2937 words; 2 figures, 1 table) 25 Abstract: With the clinical success of CTLA-4 and PD-1 blockade in treating malignancies, 26 there is tremendous interest in finding new ways to augment anti-tumor responses by targeting 27 other inhibitory molecules.
    [Show full text]
  • Evaluating the Potential for B7-H4 As an Immunoregulatory Target Heather L
    Published OnlineFirst March 21, 2017; DOI: 10.1158/1078-0432.CCR-15-2440 Molecular Pathways Clinical Cancer Research Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target Heather L. MacGregor1,2 and Pamela S. Ohashi1,2,3 Abstract With the clinical success of CTLA-4 and PD-1 blockade in malignancies. This high expression by tumors in combination treating malignancies, there is tremendous interest in finding with its low or absent protein expression in normal tissues new ways to augment antitumor responses by targeting other makes B7-H4 an attractive immunotherapeutic target. Preclin- inhibitory molecules. In this review, we describe one such ical investigation into B7-H4–specific chimeric antigen receptor molecule. B7-H4, a member of the B7 family of immunoreg- (CAR) T cells, antibody-mediated blockade of B7-H4, and anti– ulatory proteins, inhibits T cell proliferation and cytokine pro- B7-H4 drug conjugates has shown antitumor efficacy in mouse duction through ligation of an unknown receptor expressed by models. The first clinical trials have been completed to assess the activated T cells. Notably, B7-H4 protein expression is observed safety and efficacy of a B7-H4 fusion protein in ameliorating in a high proportion of patients' tumors across a wide variety of rheumatoid arthritis. Clin Cancer Res; 23(12); 2934–41. Ó2017 AACR. Background Expression and function of B7-H4 B7-H4 transcripts have been detected in a wide variety of tissues The B7 family of immunoregulatory proteins is composed (2, 7, 8), whereas B7-H4 protein expression is tightly regulated of 10 members—B7-1 (CD80), B7-2 (CD86), PD-L1 (B7-H1, and shows limited expression in most normal tissues (3, 7, 9–14).
    [Show full text]
  • Evaluating the Role of B7-H4 As a Suppressor of Tumor Infiltrating Lymphocytes and a Target for Immunotherapy in Breast Cancer Elizabeth C
    Evaluating the role of B7-H4 as a suppressor of tumor infiltrating lymphocytes and a target for immunotherapy in breast cancer Elizabeth C. Wescott1,3, Paula I. Gonzalez-Ericcson, M.D.3, Violeta Sanchez3, Justin M. Balko, Pharm D, Ph.D.1,2,3 Departments of Pathology, Microbiology, and Immunology1, Medicine2, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program3, Vanderbilt-Ingram Cancer Center; Vanderbilt University [email protected] Abstract B7-H4 is expressed on EpCAM+ murine mammary cancer cells • Immunotherapy has seen broad success across cancer types and has become a key aspect of TNBC treatment, but some patients fail to respond A B7-H4+ Murine Cell Lines B • B7-H4 (VTCN1) is an alternative immune checkpoint ligand in the CD28/B7 family of 2500 molecules, like PD-L1 2000 • We observed both high and low B7-H4 expression on several mammary cancer cell 1500 1000 lines B7-H4 MFI • B7-H4 is exclusively expressed on cells bearing epithelial markers 500 • mRNA expression data from a variety of human breast cancer cell lines corroborate this 0 4T1 strong positive correlation of B7-H4 expression on epithelial cells E0771 EMT6 PyMT-B6 • B7-H4 may act as an alternative mechanism of immunologic escape in breast cancer. MMTV-NeuMMTV-NIC (A) We screened a panel of murine mammary cancer cell lines and found both high and low Background expression of B7-H4. (B) Those cells that were B7-H4+ were also EpCAM+ in multiple cell lines. Vtcn1 expression A A B C 4 3 2 1 0 Relative Normalized Expression Normalized Relative EMT6 MMTV-Neu MMTV-Neu Epithelial MMTV-Neu Mesenchymal B B7H4 high B7H4 low (A) The MMTV-Neu cell line consists of epithelial and mesenchymal cell phenotypes.
    [Show full text]
  • Diabetes with the Development of Autoimmune VTCN1 (B7-H4
    Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune This information is current as Diabetes of October 1, 2021. Ilian A. Radichev, Lilia V. Maneva-Radicheva, Christina Amatya, Maryam Salehi, Camille Parker, Jacob Ellefson, Paul Burn and Alexei Y. Savinov J Immunol published online 15 January 2016 Downloaded from http://www.jimmunol.org/content/early/2016/01/15/jimmun ol.1403251 Supplementary http://www.jimmunol.org/content/suppl/2016/01/15/jimmunol.140325 http://www.jimmunol.org/ Material 1.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 15, 2016, doi:10.4049/jimmunol.1403251 The Journal of Immunology Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes Ilian A.
    [Show full text]
  • Viewer Tool ( 4
    BRIEF COMMUNICATION www.jasn.org Comparison of Glomerular and Podocyte mRNA Profiles in Streptozotocin-Induced Diabetes † † † ‡ † Jia Fu,* Chengguo Wei, Kyung Lee, Weijia Zhang, Wu He, Peter Chuang, Zhihong Liu,* † and John Cijiang He § *National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; †Division of Nephrology, Department of Medicine, ‡Flow Cytometry Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York; §Renal Program, James J. Peters VA Medical Center at Bronx, New York. ABSTRACT Evaluating the mRNA profile of podocytes in the diabetic kidney may indicate STZ induction alone.10 In order to spe- genes involved in the pathogenesis of diabetic nephropathy. To determine if the cifically label and isolate podoctyes, we 2 2 podocyte-specific gene information contained in mRNA profiles of the whole crossed the eNOS / mice with the IRG glomerulus of the diabetic kidney accurately reflects gene expression in the isolated mice11 that ubiquitously express a red 2/2 podocytes, we crossed Nos3 IRG mice with podocin-rtTA and TetON-Cre mice fluorescent protein prior to Cre-mediated for enhanced green fluorescent protein labeling of podocytes before diabetic injury. recombination and an enhanced green Diabetes was induced by streptozotocin, and mRNA profiles of isolated glomeruli fluorescent protein (EGFP) following re- and sorted podocytes from diabetic and control mice were examined 10 weeks combination. These mice were further later. Expression of podocyte-specific markers in glomeruli was downregulated in bred with podocin-rtTA and TetON-Cre diabetic mice compared with controls. However, expression of these markers was (LC1) transgenic mice for inducible not altered in sorted podocytes from diabetic mice.
    [Show full text]
  • Immune Regulation Proteins Focus: Immune Checkpoint Proteins, Interleukins & Cytokines
    CC MM Chimerigen Laboratories ChimeThe Experts for Highrigen Quality Fusion ProteinsLaboratories www.adipogen.com 2nd Edition Immune Regulation Proteins Focus: Immune Checkpoint Proteins, Interleukins & Cytokines Mouse Immune Checkpoint & Interleukin Proteins for In Vivo Studies Ask for PID ProdUct NamE CHI-MF-110A4 CD152 [CTLA-4] (mouse):Fc (mouse) (rec.) CHI-MF-120A4 CD152 [CTLA-4] (mouse):Fc (mouse) (rec.) (non-lytic) BULK! CHI-MF-110PDL1 CD274 [B7-H1/PD-L1] (mouse):Fc (mouse) (rec.) CHI-MF-120PDL1 CD274 [B7-H1/PD-L1] (mouse):Fc (mouse) (rec.) (non-lytic) CHI-MF-110PD1 CD279 [PD-1] (mouse):Fc (mouse) (rec.) CHI-MF-110B7H4 B7-H4 (mouse):Fc (mouse) (rec.) CHI-MF-11002 IL-2 (mouse):Fc (mouse) (rec.) CHI-MF-12002 IL-2 (mouse):Fc (mouse) (rec.) (non-lytic) CHI-MF-11021 IL-21 (mouse):Fc (mouse) (rec.) Contents CHI-MF-12021 IL-21 (mouse):Fc (mouse) (rec.) (non-lytic) Immune Checkpoint Proteins B7-CD28 Superfamily 2–3 Other Immune Checkpoint Proteins 4 NEW Checkpoints Overview [Wallchart] 5 mIL-35/Fc – An Inhibitory Cytokine TIM Family 6 Butyrophilin-like 2 6 Biological activity tested in vivo. Costimulation & Immune Regulation Factors 7 IL-35 suppresses T cell proliferation and converts naïve T cells into IL-35-producing induced regulatory T cells (iTr35). iTr35 cells can mediate self tolerance and prevent Interleukins & Cytokines autoimmunity in an IL-35-dependent manner. IL-35 is considered to have a potential therapeutic effect against immune diseases and could promote the development Interleukins Overview 8–10 of different kinds of vaccines for immunotherapy against cancer and be promising Specific IL-15Ra Antagonist 10 to cure autoimmune and inflammatory diseases.
    [Show full text]
  • Immune Checkpoint Reagents Brochure
    www.adipogen.com Immune Checkpoint Reagents Focus: T cells COLLABORATING WITH Regulation and activation of T lymphocytes depend on signaling by the T cell receptor (TCR) and also by cosignaling receptors that deliver negative or positive signals (see page 5 for an overview chart). The amplitude and quality of the immune response of T cells is controlled by an equilibrium between costimulatory and inhibitory signals called immune checkpoints. Under normal physiological conditions, immune check- points are crucial for the maintenance of self-tolerance and to protect tissues from damage during pathogenic infection. Manipulations of stimulatory or inhibitory im- mune checkpoints using monoclonal antibodies, soluble receptors (fusion proteins) or small molecules may provide therapeutic strategies for autoimmune diseases, tumor growth, infectious diseases and transplantation by decreasing or enhancing SELECTED REVIEW ARTICLES T cell activity. IHC-competent antibodies and highly sensitive immunoassays are of The future of immune checkpoint therapy: P. great importance for diagnostic and therapeutic control purposes. Sharma & J.P. Allison; Science 348, 56 (2015) • Immune checkpoint blockade in infectious dis- eases: M.N. Wykes & S.R. Lewin; Nat. Rev. Immu- nol. 18, 91 (2018) • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy: S.C. Wei, Highly Sensitive PD-1/PD-L1 ELISA Kits et al.; Cancer Discov. 8, 1069 (2018) JUST RELEASED CONTENTS Biomarker for Immuno-Oncology & PD-1/PD-1L Pathway 2 ICOS/ICOSL Pathway 3 Autoimmune Diseases CTLA-4/CD80/CD86/CD28 Network 4 NEW PD-1 (human) ELISA Kit Immune Checkpoint Wallchart 5 AG-45B-0015 96 wells LAG-3/MHC/TCR Pathway 6 Specificity: Detects soluble human PD-1 (sPD-1) in biological fluids.
    [Show full text]
  • Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: a Pilot Study
    Journal of Clinical Medicine Article Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study Lu Cao 1,2,†, Prashanth Prithviraj 3,4,†, Ritu Shrestha 1,2 , Revati Sharma 3,4, Matthew Anaka 5, Kim R. Bridle 1,2, George Kannourakis 3,4, Darrell H.G. Crawford 1,2 and Aparna Jayachandran 1,2,3,* 1 Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia; [email protected] (L.C.); [email protected] (R.S.); [email protected] (K.R.B.); [email protected] (D.H.C.) 2 Faculty of Medicine, University of Queensland, Brisbane, QLD 4120, Australia 3 Fiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia; [email protected] (P.P.); [email protected] (R.S.); [email protected] (G.K.) 4 School of Science, Psychology and Sports, Federation University Australia, Ballarat, VIC 3350, Australia 5 Department of Medical Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada; [email protected] * Correspondence: [email protected]; Tel.: +61-4-2424-8058 † Equal contributors. Abstract: Cholangiocarcinoma (CCA) is a hepatobiliary malignancy associated with steadily increas- ing incidence and poor prognosis. Ongoing clinical trials are assessing the effectiveness and safety of a few immune checkpoint inhibitors (ICIs) in CCA patients. However, these ICI treatments as monotherapies may be effective for a proportion of patients with CCA. The prevalence and distri- Citation: Cao, L.; Prithviraj, P.; Shrestha, R.; Sharma, R.; Anaka, M.; bution of other immune checkpoints (ICs) in CCA remain unclear. In this pilot study, we screened Bridle, K.R.; Kannourakis, G.; databases of CCA patients for the expression of 19 ICs and assessed the prognostic significance of Crawford, D.H.G.; Jayachandran, A.
    [Show full text]
  • Gene Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section Mini Review VTCN1 (V-set domain containing T cell activation inhibitor 1) Panduka Samarawardana, Kenneth R Shroyer Department of Pathology, University of Colorado at Denver and Health Sciences Center, USA (PS); Department of Pathology, Stony Brook University Medical Center, Aurora, CO 80045, USA (KRS) Published in Atlas Database: February 2008 Online updated version: http://AtlasGeneticsOncology.org/Genes/VTCN1ID44144ch1p13.html DOI: 10.4267/2042/38604 This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology Identity Protein Hugo: VTCN1 Description Other names: B7H4; B7-H4; B7S1; B7X; B7h.5; The predicted 282-amino acid B7-H4 protein contains a FLJ22418; PRO1291; RP11-229A19.4 2-amino acid intracellular domain, a large hydrophobic Location: 1p13.1 type 1 transmembrane domain and an extracellular DNA/RNA domain (Prasad et al., 2003). Expression Description Prasad et al. (2003) showed that B7-H4 is expressed in The VTCN1 (B7-H4) gene located in chromosome professional antigen presenting cells. Although B7-H4 1p13.1, consists of six exons and five introns and the is overexpressed in several human cancers including coding region spans 849 bp. The mature protein is ovary, endometrium, lung and kidney, its expression is coded by the exons 3, 4, and part 5 while exons 1 and 2 limited in normal tissues. Shroyer et al. (2005) showed encodes a signal peptide. The IgV-IgC domain, that there is a limited focal expression of B7-H4 by comprised of the extracellular region, is coded by immunohistochemistry in several normal human tissues exons 3, 4 and parts of 5 (Chen et al., 2003).
    [Show full text]
  • Profiling of Inhibitory Immune Checkpoints in Glioblastoma: Potential Pathogenetic Players
    ONCOLOGY LETTERS 20: 332, 2020 Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players SALVO DANILO LOMBARDO1, ALESSIA BRAMANTI2, ROSELLA CIURLEO2, MARIA SOFIA BASILE2, MANUELA PENNISI3, RITA BELLA4, KATIA MANGANO3, PLACIDO BRAMANTI2, FERDINANDO NICOLETTI3 and PAOLO FAGONE3 1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A‑1090 Vienna, Austria; 2IRCCS Centro Neurolesi Bonino Pulejo, I‑98124 Messina; Departments of 3Biomedical and Biotechnological Sciences and 4Medical Sciences, Surgery and Advanced Technologies, University of Catania, I‑95123 Catania, Italy Received July 30, 2020; Accepted October 6, 2020 DOI: 10.3892/ol.2020.12195 Abstract. Glioblastoma (GBM) represents the most frequent dard of care for GBM consists of surgical resection, followed glial tumor, with almost 3 new cases per 100,000 people per by radiotherapy and chemotherapy with temozolomide (4). year. Despite treatment, the prognosis for GBM patients remains Despite treatment, the prognosis for GBM patients remains extremely poor, with a median survival of 14.6 months, and a extremely poor, with a median survival period of 14.6 months, 5‑year survival less than 5%. It is generally believed that GBM and the 5‑year survival is less than 5% (4). creates a highly immunosuppressive microenvironment, sustained In recent years, great progress has been made in the area by the expression of immune‑regulatory factors, including inhibi‑ of immunotherapy and accumulating preclinical and clinical tory immune checkpoints, on both infiltrating cells and tumor data seem to suggest potential novel therapeutic avenues for cells. However, the trials assessing the efficacy of current immune GBM patients (5,6). It is generally believed that GBM creates a checkpoint inhibitors in GBM are still disappointing.
    [Show full text]